BD Announces Additional Sizes of Halo One Thin-Walled Guiding Sheath

Thin-walled guiding sheath now available with introducer kit variations and longer lengths

FRANKLIN LAKES, N.J. (Dec. 20, 2021) – BD (Becton, Dickinson and Company) announced the launch of additional sizes of the Halo One^™ Thin-Walled Guiding Sheath for use in peripheral arterial and venous procedures requiring percutaneous introduction of intravascular devices.

The portfolio expansion includes new introducer kits and 6F guiding sheaths, which received clearance from the U.S. Food and Drug Administration and are now commercially available. The broad size offering is now available in 4, 5 and 6F (French size) and consists of 10 cm, 25 cm, 45 cm, 70 cm and 90 cm lengths.

“I'm excited about this portfolio expansion for the Halo One^™ Thin-Walled Guiding Sheath,” says John Phillips, MD, System Director for the OhioHealth Vascular Institute. “Now we have a thin-walled, braided sheath platform that’s capable of both distal and proximal interventions with the potential to help reduce access site complications.”

Halo One^™ Thin-Walled Guiding Sheath consists of a thin-walled (1 French wall thickness) sheath made from braided single-lumen tubing, fitted with a female luer hub at the proximal end and a formed atraumatic distal tip, and is designed for uses including femoral, radial, popliteal, tibial and pedal access procedures. The thin-walled design reduces the size of the arteriotomy compared to standard sheaths of equivalent French size, which can help to minimize access site complications.[1] Halo One^™ Thin-Walled Guiding Sheath’s broad size offering provides the only thin-walled guiding sheath in the U.S. with lengths suitable for distal peripheral intervention.

More information about the Halo One^™ Thin-Walled Guiding Sheath, including indications for use and safety information may be found on the BD website: Halo One™ Thin-Walled Guiding Sheath - BD.
 

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.        

[1]Ortiz, Daniel, et al. “Access site complications after peripheral vascular interventions: incidence, predictors, and outcomes.” Circulation: Cardiovascular Interventions 7.6 (2014): 821-828